Congress mandates free naloxone at hospital discharge for overdose prevention
H.R. 5120 — HANDS Act · Filed by Brittany Pettersen (D-CO) · 3 cosponsors · Introduced Sep 3, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires Medicare, Medicaid, and military health insurance (TRICARE) to cover opioid overdose reversal drugs (naloxone/Narcan) at no cost to patients when dispensed at hospital discharge or emergency department visits, starting January 1, 2026. Patients identified as at-risk for overdose receive the drug free, with no deductibles or copays, and hospitals receive federal reimbursement for the cost.
Why we flagged it
The bill's core function is to mandate no-cost coverage of a specific preventive medication across three federal health programs. It is a public health measure, not a tax provision, deregulation, or appropriation.
What the text implies
- Pharmaceutical manufacturers (naloxone producers) gain guaranteed federal reimbursement for a defined population without price negotiation constraints explicitly stated in the bill, potentially creating a stable revenue stream.
- The bill does not specify reimbursement rates, leaving CMS discretion to set payment amounts—manufacturers may lobby for higher rates, and the lack of explicit rate-setting language could invite future disputes.
The full analysis lists 4 implications of this text.
Who stands to gain
naloxone manufacturers (Ampharos Pharmaceuticals, Emergent BioSolutions, Pfizer, others); pharmaceutical wholesalers and distributors; hospitals and emergency departments (reimbursement for dispensing)